linjc16/ctgov huggingface dataset:
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings

Study Overview
=================
Brief Summary
-----------------
Familial Mediterranean fever (FMF ,recurrent polyserositis ,periodic disease) is an autosomal recessive auto inflammatory disease which primarily affect population surrounding the Mediterranean basin (Arabs , Turks ,Armenians, Jews ).Despite its striking symptoms pattern FMF was first described as distinct entity only in 1945. It is characterized by recurrent attacks of fever , peritonitis ,pleurisy , arthritis , or erysipelas like skin disease. The most dangerous complication of this disease is secondary amyloidosis . FMF diagnosis is mainly clinical, and the genetic testing is indicated to support it . Uncommonly, amyloidosis may develop in individuals carrying two Familial Mediterranean fever gene (MEFV ) mutations without overt clinical symptoms of FMF, a condition designated as phenotype II. Furthermore, two MEFV mutations may be harbored without signs or symptoms of FMF nor of reactive amyloidosis. This 'silent' homozygous or compound heterozygote state is termed phenotype III.

Official Title
-----------------
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings

Conditions
-----------------
Familial Mediterranean Fever

Intervention / Treatment
-----------------
* Diagnostic Test: CBC with differential ,ESR ,CRP, Amyloid level , FMF gene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A- all children diagnosed as FMF according to Tel hashomer criteria aged below 18 years: The presence of at least 2 of the following 5 criteria after exclusion of other causes can diagnose FMF with high sensitivity: Fever axillary temperature of >38ᵒC, 6-72 h of duration, ≥3 attacks Abdominal pain 6-72 h of duration ≥3 attacks Chest pain 6-72 h duration≥ 3 attacks Arthritis 6-72 h duration ≥3 attacks, oligoarthritis Family history of FMF*(11) B-sisters and brothers of a child with FMF with clinical or subclinical manifestation of FMF. Exclusion Criteria: Children with other auto inflammatory diseases, or with other diseases. Persons above 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CBC | leucocytosis | 12 month | 
| amyloid level | high in untreated patients | 12 month | 
| FMF gene | positive or negative | 12 month |
Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw

Study Overview
=================
Brief Summary
-----------------
To determine if a manual blood loss can be detected using the non-invasive blood monitor.

Official Title
-----------------
Clinical Evaluation of the Zynex Blood Volume Monitor (CM1500) in Healthy Adult Volunteers During a Blood Draw

Conditions
-----------------
Blood Loss

Intervention / Treatment
-----------------
* Device: CM1500


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteer between 18 to 50 years of age weight between 157 to 220 lbs Exclusion Criteria: unstable or untreated cardia disease alcohol consumption in 24 hours prior to screening tobacco use in 4 hours prior to screening pregnancy infection Hemoglobin < 12.5 g/dL at time of procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Blood draw<br>CM1500 with blood draw | Device: CM1500<br>* blood volume monitor<br>|
| Sham Comparator: No blood draw<br>CM 1500 with no blood draw | Device: CM1500<br>* blood volume monitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detect change in blood volume by non-invasive monitoring during whole blood draw |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood loss, hemorrhage, hemorrhagic shcok
Luteal Phase Commencing of Growth Hormone

Study Overview
=================
Brief Summary
-----------------
Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder

Official Title
-----------------
Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: Norditropin pen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Poor responder Exclusion Criteria: FSH >20 IU

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>poor responder | Drug: Norditropin pen<br>* 12 IU per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mature oocyte number |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
poor responder, growth hormone, luteal
Resident Memory T Cells in Vitiligo

Study Overview
=================
Brief Summary
-----------------
This study aims to detect the presence and diversity of Tissue resident memory T cell populations in early and late cases of generalized non-segmental Vitiligo.

Detailed Description
-----------------
Written informed consent obtained from every participant. Detailed history taking including onset, course, duration of the disease, aggravating factors and received medications VASI score assessed in every patient. Patients photographed, divided into two groups early & late cases and 3 mm punch biopsies will be taken from perilesional and non lesional skin. Biopsies processed and stained for CD8 & CD69 in cases of early group, & late group and controls by immunofluorescence.

Official Title
-----------------
Tissue Resident Memory T Cells in Early & Late Cases of Generalized Non-segmental Vitiligo

Conditions
-----------------
Vitiligo

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with Generalized non-segmental Vitiligo ( lesions in more than one anatomical site ). Both genders. Early group: onset less than or equal 6 months. Late group: onset more than 6 months Exclusion Criteria: Localized or Segmental Vitiligo. Age < 14 years. Pregnant females Patient who received treatment of any type within the last 3 months for the late group. Patients with other skin diseases or immunosuppression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD8+ immunofluorescence | Number of Tissue resident Memory cells by positively stained by CD8+ in early and late generalized non segmental vitiligo patients | 6months-1 year | 
| CD69+ immunofluorescence | Number of Tissue resident Memory cells by positively stained by CD8+ in early and late generalized non segmental vitiligo patients | 6months-1 year | 
| Double CD8+ and CD69+ immunofluorescence | Number of Tissue resident Memory cells by double stained by CD8+ &CD 69+ in early and late generalized non segmental vitiligo patients | 6months-1 year | 
| VASI | Vitiligo Area and Severity index minimum 0 maximum 100, the larger the number the worse the condition | 6months-1 year |
Effectiveness of Modified Health Belief Model Based Intervention to Reduce Body Mass Index

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to Effectiveness of Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age in Overweight Junior High School Students.

Detailed Description
-----------------
The purpose of this study is to Effectiveness of Modified Health Belief Model Based Intervention to change behavior to Reduce Body Mass Index for Age in Overweight Junior High School Students.

Official Title
-----------------
Effectiveness of Modified Health Belief Model Based Intervention to Reduce Body Mass

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Behavioral: change behavior


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: junior High School Students age 12 - 15 years bmi for age ≥ median +1 SD Read and write Thai Language Agree to participate voluntarily . Exclusion Criteria: students with medical conditions diagnosed by a physician and a barrier to participation .

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: change behavior<br>Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students. | Behavioral: change behavior<br>* Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age<br>* Other names: change behavior intervention;|
| Experimental: lifestyle behavior<br>study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students. | Behavioral: change behavior<br>* Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age<br>* Other names: change behavior intervention;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass Index | Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age in Overweight Junior High School Students durationof program 6 month | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heath literacy for obesity in Junior High School Students. | assessment to Heath literacy for obesity in Junior High School Students by questionnaire. | 6 month |
Clinical Audit of Managment of Gausher Disease in Children

Study Overview
=================
Brief Summary
-----------------
clinical audit on managment of gausher disease in children

Detailed Description
-----------------
The main aim of study is to evaluate the management of Gausher disease patient under enzyme replacement therapy in Assuit University Children's Hospital and compare our policy for management with International guideline of management of Gausher disease in children (8) Type of study : clinical audit Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital. Site of study :Assuit University children's Hospital Methodiological Exclusion criteria 3-New diagnosed cases not on ERT. 2-other lipid storage disease. Patient& method The study will include 42 diagnosed Gaucher disease patient under enzyme replacement therapy attend the hematology unit in Assuit University Children's Hospital in one year Reviewing the proposal will be carried out before starting via the ethical committee of Assuit Faculty of Medicine. Ethical consideration The aim of the study will be explained to each patient before beginning of the process. We will compare our policy in management of Gausher disease with International guideline of management of gausher disease 1-cases of Gaucher type 2.

Official Title
-----------------
Assiut University Children 's Hospital

Conditions
-----------------
Gaucher Disease

Intervention / Treatment
-----------------
* Diagnostic Test: gausher disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital. Exclusion Criteria: 1-cases of Gaucher type 2. 2-other lipid storage disease. 3-New diagnosed cases not on ERT.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gausher disease in children<br>• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital. | Diagnostic Test: gausher disease<br>* lab investigation and radio logical<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the management of Gausher disease patient under enzyme replacement therapy in Assuit University Children's Hospital and compare our policy for management with International guideline of management of Gausher disease in children (8) | • Type of study : clinical audit | one year |
Effectiveness of Resin Sealants: Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
This retrospective cohort study assessed sealant clinical success applied to pit and fissure by dental undergraduate students at Piracicaba Dental School - Brazil.

Detailed Description
-----------------
A population presenting 1st/2nd permanent molars with sealed occlusal surfaces were considered. Dental records were reviewed for: patient's caries risk (High/Low); operator experience (scores 1 to 4, beginners to seniors); number of follow-up visits; isolation procedure; sealant/tooth type; and age at placement. Posteriorly, the patients were called to dental evaluation and the sealed teeth were classified regarding the sealant presence, partial presence or absence, with or without caries, or sealant replacement to a restorative material in Satisfactory or Unsatisfactory, considering the caries presence/absence. Successful outcome was considered in the caries absence.

Official Title
-----------------
A Retrospective Cohort Study on Clinical Success of Resin Sealants

Conditions
-----------------
Dental Caries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A population presenting first and second permanent molars with sealed occlusal surfaces by dental undergraduate students at Piracicaba Dental School Brazil. Exclusion Criteria: First and second permanent molars with sealed occlusal surfaces by dentistry.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Probability (%) of the caries development in the treated teeth assessed by Kaplan-Meier survival analysis (Bioestat 5.3). | Outcome mensuration by clinical examination (caries prevention and retention sealant) and bitewing radiograph. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pit and fissure sealants, Dental Caries, Prevention, Dental undergraduate students, patient's caries risk
Hematocrit Effect on a Blood Glucose Monitor

Study Overview
=================
Brief Summary
-----------------
This study assesses the repeatability precision of a blood glucose monitoring system pursuant to ISO 15197

Detailed Description
-----------------
This study assesses the repeatability precision the blood glucose monitoring systems for personal use TJ100 pursuant to ISO 15197:2015 guidelines

Official Title
-----------------
Evaluation of the Hematocrit Effect on the Blood Glucose Monitor for Personal Use JT100

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Diagnostic Test: blood glucose measurement, blood glucose monitor for personal use
* Diagnostic Test: blood glucose measurement, laboratory reference device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients with clinical indication for blood glucose testing Signed form of consent Minimum age of 18 years Subjects are legally competent and capable to understand character, meaning and consequences of the study Exclusion Criteria: Pregnancy or lactation Severe acute disease (at study physician's discretion) Acute or chronic diseases with inherent risk of aggravation by the procedure (at study physician's discretion) Current constitution that does not allow participating in the study (e.g. hematocrit out of the devices's specifications, medication known to influence blood glucose measurements; Appendix A of ISO 15197) Being unable to give informed consent Age younger than 18 years Legally incompetent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subject glucometer measurement<br> | Diagnostic Test: blood glucose measurement, blood glucose monitor for personal use<br>* measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)<br>* Other names: measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100);Diagnostic Test: blood glucose measurement, laboratory reference device<br>* measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| repeatability precision | Assessment of the analytical measurement performance of the blood glucose monitor based on procedures defined in DIN EN ISO 15197 | day 1 |
Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical outcomes in patients with recurrent corneal erosions who received anterior stromal puncture by use of neodymium:yttrium-aluminum-garnet (Nd:YAG) laser.

Detailed Description
-----------------
Participants: From 2000 to 2005, thirty-three eyes in 33 patients with unilaterally recurrent corneal erosions who showed poor response to conservative managements and were treated with Nd:YAG laser were studied. Intervention: Anterior corneal stromal puncture with Nd:YAG laser was performed in the loosened epithelium or epithelial defect area. The causes and frequency of corneal erosions and the spot numbers and total energy of the Nd:YAG laser were recorded. Slit-lamp biomicroscopic examination, refraction, corneal topography, and times of laser were reviewed. A questionnaire regarding the preoperative and postoperative difference in the intensity of pain and frequency of corneal erosion was provided. Main Outcome Measures: Rate of recurrence and pain assessment by numerical rating scale.

Official Title
-----------------
Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser

Conditions
-----------------
Recurrent Corneal Erosion, Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with recurrent corneal erosions who showed poor response to conservative managements and were treated with Nd:YAG laser. Exclusion Criteria: Slit-lamp biomicroscopic examination in both eyes of patient showed any evidence of anterior basement membrane dystrophy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 71 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cure rate of recurrent corneal erosions (frequency of attack and numbers of Nd: YAG laser treatment), intensity of pain relief and visual acuity. |  | Before treatment, weekly after the treatment, and monthly after symptom relief | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nd: YAG laser, recurrent corneal erosions, trauma, anterior stromal puncture